Nasdaq · CIK 0001835022
COYA Coya Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Aug 19, 2025. Close $4.95 on Oct 9, 2026, +31% from the 52-week low and -33% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
COYAOct 9, 2026 · close 4.95
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Coya Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | David S Snyder Chief Financial Officer buy | $13k 1,800 shares | +26% | - | |
| 61Notable | Arun Swaminathan Chief Executive Officer buy | $37k 5,000 shares | +100% | - | |
| 54Moderate | Arun Swaminathan Chief Executive Officer buy | $37k 5,000 shares | - | - | |
| 38Weak | Fred Grossman Chief Medical Officer buy | $20k 2,710 shares | - | - |
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Dov A Goldstein Md director | MOption exercise Common Stock, par value $0.0001 per share | +17,557 | $1.09 | $19k | 27,557 | Aug 19, 2025 |
| Aug 18, 2025 | Dov A Goldstein Md director | MOption exercise Stock Option (right to buy)derivative | -17,557 | $0.00 | $0 | 0 | Aug 19, 2025 |
| Feb 25, 2025 | Wilbur L Ross Jr director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Feb 25, 2025 |
| Feb 25, 2025 | Dieter Weinand director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Feb 25, 2025 |
| Feb 25, 2025 | Dov A Goldstein Md director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Feb 25, 2025 |
| Feb 25, 2025 | Anabella Villalobos director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Feb 25, 2025 |
| Feb 25, 2025 | Ann Lee director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Feb 25, 2025 |
| Jan 9, 2025 | David S Snyder Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +140,562 | $0.00 | $0 | 140,562 | Jan 13, 2025 |
| Jan 9, 2025 | Arun Swaminathan Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +240,964 | $0.00 | $0 | 240,964 | Jan 13, 2025 |
| Jan 9, 2025 | Fred Grossman Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +140,562 | $0.00 | $0 | 140,562 | Jan 13, 2025 |
| Jan 9, 2025 | Howard Berman director | AGrant or award Stock Option (right to buy)derivative | +150,602 | $0.00 | $0 | 150,602 | Jan 13, 2025 |
| Jan 1, 2025 | Dieter Weinand director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 3, 2025 |
| Jan 1, 2025 | Anabella Villalobos director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 3, 2025 |
| Jan 1, 2025 | Ann Lee director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 3, 2025 |
| Jan 1, 2025 | Wilbur L Ross Jr director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 3, 2025 |
| Jan 1, 2025 | Dov A Goldstein Md director | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 3, 2025 |
| Nov 14, 2024 | David S Snyder Chief Financial Officer | POpen-market purchase Common Stock, par value $0.0001 per share | +1,800 | $7.19 | $13k | 8,800 | Nov 14, 2024 |
| Nov 13, 2024 | Arun Swaminathan Chief Executive Officer | POpen-market purchase Common Stock, par value $0.0001 per share | +5,000 | $7.36 | $37k | 10,000 | Nov 13, 2024 |
| Nov 11, 2024 | Arun Swaminathan Chief Executive Officer | POpen-market purchase Common Stock, par value $0.0001 per share | +5,000 | $7.34 | $37k | 5,000 | Nov 12, 2024 |
| Nov 11, 2024 | Fred Grossman Chief Medical Officer | POpen-market purchase Common Stock, par value $0.0001 per share | +2,710 | $7.37 | $20k | 2,710 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Howard Bermandirector
- Dov A Goldstein Mdcfo, officer, director
- Fred GrossmanChief Medical Officer
- Ann Leedirector
- Wilbur L Ross Jrdirector
- David S SnyderChief Financial Officer
- Arun SwaminathanChief Executive Officer
- Anabella Villalobosdirector
- Dieter Weinanddirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.